title: Long-term utility and durability of the therapeutic effects of bimatoprost 0.03% for eyelash augmentation in healthy Asian subjects.
abstract: BACKGROUND
  Eyelashes of Asians differ from those of Caucasians in morphology and growth characteristics. Ethnic differences also exist for the tolerability profile of prostaglandin analogues.
  
  
  OBJECTIVE
  To evaluate the long-term utility and durability of bimatoprost 0.03% in eyelash augmentation in Asian females.
  
  
  METHODS
  One cohort received bimatoprost 0.03% for 36 weeks and another for 20 weeks, with the latter cohort followed for 16 weeks after treatment cessation. The primary endpoint was the percent change in eyelash length at week 20. Secondary measures included percent change in eyelash thickness and darkness, physician's Global Eyelash Assessment and patient satisfaction.
  
  
  RESULTS
  At week 20, eyelash length was enhanced in a time-dependent manner, with maximum improvement achieved (19.3%; p < 0.0001). Significant improvements in thickness and darkness were also achieved (22.9%, 6.0%; p < 0.0001). 77.8% of subjects improved by ≥1 grade on Global Eyelash Assessment, with 83.1% satisfied/very satisfied. Improvements were maintained with ongoing treatment to 36 weeks, while these effects were progressively lost with discontinuation.
  
  
  CONCLUSIONS
  Bimatoprost 0.03% safely enhanced eyelashes in Asian females, maintained with ongoing treatment. Cessation of treatment was associated with progressive loss of effects.
authors.affiliation: Department of Dermatology and Institute of Human-Environment Interface Biology, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Ohsang
authors.initials: O
authors.lastname: Kwon
authors.forename: Jin Yong
authors.initials: JY
authors.lastname: Kim
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Paik
authors.forename: Hye Chan
authors.initials: HC
authors.lastname: Jeon
authors.forename: Ye-Jin
authors.initials: YJ
authors.lastname: Jung
authors.forename: Yoonhee
authors.initials: Y
authors.lastname: Lee
authors.forename: Ji Hye
authors.initials: JH
authors.lastname: Baek
authors.forename: Ji Hoon
authors.initials: JH
authors.lastname: Chun
authors.forename: Won-Soo
authors.initials: WS
authors.lastname: Lee
authors.forename: Jun Young
authors.initials: JY
authors.lastname: Lee
authors.forename: John D
authors.initials: JD
authors.lastname: Rogers
authors.forename: Michael
authors.initials: M
authors.lastname: Halstead
authors.forename: Hee Chul
authors.initials: HC
authors.lastname: Eun
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000577:Amides / Q000008:administration & dosage*; D000704:Analysis of Variance; D044466:Asian People / Q000706:statistics & numerical data*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015331:Cohort Studies; D003357:Cosmetic Techniques; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004954:Esthetics; D005140:Eyelashes / Q000187:drug effects* / Q000254:growth & development*; D005260:Female; D006801:Humans; D008134:Long-Term Care; D061214:Patient Safety; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D011446:Prospective Studies; D012846:Singapore
chemical_list: D000577:Amides; D003008:Cloprostenol; D000069580:Bimatoprost